CeraPedics to Present at Medtech Insight's ``Investment In Innovation'' Conference.Business Editors/Health/Medical Writers Medtech Insight 2004 Investment in Innovation IRVINE, Calif.--(BUSINESS WIRE)--Feb. 11, 2004 CeraPedics will be presenting on February 24 at Medtech Insight's Prestigious "Investment In Innovation" Event, taking place February 24-25, 2004 at the Hyatt Regency Irvine in Irvine, California Irvine is an incorporated city in Orange County, California, United States. It is a planned city, mainly developed by the Irvine Company since the 1960s. Formally incorporated on December 28 1971, the 69.7 square mile (180.5 km²) city has a population of 202,079 (as of 2007). . CeraPedics is an orthopedic company focused on developing osteobiologic products using its proprietary small peptide (P-15(TM)) technology platform. CeraPedics possesses the exclusive world-wide orthopedic rights to the P-15 technology through the University of California The University of California has a combined student body of more than 191,000 students, over 1,340,000 living alumni, and a combined systemwide and campus endowment of just over $7.3 billion (8th largest in the United States). , and its first generation bone substitute material is currently under consideration by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. . At the conference, CeraPedics will introduce two distinct osteobiologic products utilizing the P-15 technology platform: 1) P-15 enhanced bone substitute branded CerOss P-15, and 2) P-15 coated metal implants. By synthetically replicating the cellular role of collagen with the small peptide (P-15) and irreversibly binding it to a suitable matrix such as particulate par·tic·u·late adj. Of or occurring in the form of fine particles. n. A particulate substance. particulate composed of separate particles. calcium phosphate calcium phosphate n. 1. A colorless deliquescent powder, Ca(H2PO4)2, used in baking powders, as a plant food, as a plastic stabilizer, and in glass. 2. or metallic implants, a biomimetic environment for bone regeneration is created. Peer reviewed clinical dental literature and pre-clinical orthopedic data suggest that CerOss P-15 is more effective than existing allograft allograft: see transplantation, medical. (cadaver cadaver /ca·dav·er/ (kah-dav´er) a dead body; generally applied to a human body preserved for anatomical study.cadav´ericcadav´erous ca·dav·er n. bone) and synthetic bone substitutes. In addition, large animal studies suggest that the P-15 bone substitute is equivalent to the gold standard of graft material, autograft autograft: see transplantation, medical. bone (the hosts own bone). In-vitro data further suggests that P-15 coated titanium implants may increase the bone to implant contact which would allow for improved implant integration. Within the field of orthopedics, CeraPedics initially intends to position CerOss P-15 as a bone graft bone graft Orthopedic surgery Sterilized bony tissue, often of cadaveric origin, used to fill and/or 'sculpt' bone defects Indications Spinal fusion, revision of failed articular prostheses, filling traumatic or malignant bone defects, or periodontal defects. substitute for use in spinal and trauma applications. Independent research estimates that within orthopedics, the combined U.S. market for bone graft substitutes used in spine and trauma procedures was $244.2 million in 2002. This market is estimated to grow to over $1.26 billion by 2008. About Medtech Insight Medtech Insight's "Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies" conferences are considered the premier forum for senior executives in the medical technology and investment community to preview emerging medtech companies in need of funding, acquisition and/or strategic partnership. In addition to conferences, Medtech Insight publishes the "medtech insight" newsletter, a monthly publication covering the latest trends and innovations in the medical technology industry, analyses of medtech markets through its Reports group, and offers custom consulting and market research. To register for the Irvine conference or for more information on Medtech Insight, please call Scott Pantel at (949) 219-0150 or (888) 290-2225 toll-free in the U.S., e-mail in3@medtechinsight.com, or visit http://www.medtechinsight.com/in3-10.html. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion